ArticleChemistry & biology2008
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.
Article in Chemistry & biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed.
- The emerging role of aptamers in targeted cancer immunotherapy.Molecular therapy. Oncology · 2026Review
- Navigating the next frontier in biomedicine: breakthroughs and insights in nucleic acid therapeutics.Chemical science · 2026Review
- Aptamers as target-specific recognition elements in drug delivery.Advanced drug delivery reviews · 2025Review
- Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives.Frontiers in immunology · 2025Review
- Analysis of cell signaling profiles induced by DNA aptamer-based FGFR1 agonist.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Article
- Review
- i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists.Nature communications · 2024Article
- Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.Frontiers in immunology · 2024Review
- Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles.Frontiers in immunology · 2023Review
- Antitumor efficacy of multi-targetJournal of biomedical research · 2022Article
- Aptamer-Based Probes for Cancer Diagnostics and Treatment.Life (Basel, Switzerland) · 2022Review
- Boosting antitumor response with PSMA-targeted immunomodulatory VLPs, harboring costimulatory TNFSF ligands and GM-CSF cytokine.Molecular therapy oncolytics · 2022Article
- Cancer immunomodulation using bispecific aptamers.Molecular therapy. Nucleic acids · 2022Review
- Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.ACS pharmacology & translational science · 2021Review
- Theoretical premises of a "three in one" therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review.Translational cancer research · 2021Review
- Identification and Engineering of Aptamers for Theranostic Application in Human Health and Disorders.International journal of molecular sciences · 2021Review
- Stoichiometry of multi-specific immune checkpoint RNA Abs for T cell activation and tumor inhibition using ultra-stable RNA nanoparticles.Molecular therapy. Nucleic acids · 2021Article
- The Potential of Aptamer-Mediated Liquid Biopsy for Early Detection of Cancer.International journal of molecular sciences · 2021Review
- Utility of Multivalent Aptamers to Develop Nanoscale DNA Devices against Surface Receptors.ACS omega · 2021Review
- Recent Progress and Opportunities for Nucleic Acid Aptamers.Life (Basel, Switzerland) · 2021Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
We show that a molecular scaffold can be utilized to convert a receptor binding aptamer into a receptor agonist. Many receptors (including tumor necrosis receptor family members) are activated when they are multimerized on the cell surface. Molecular scaffolds have been utilized to assemble multiple receptor binding peptide ligands to generate activators of such receptors. We demonstrate that an RNA aptamer that recognizes OX40, a member of the tumor necrosis factor receptor superfamily, can be converted into a receptor-activating aptamer by assembling two copies on an olignucleotide-based scaffold. The OX40 receptor-activating aptamer is able to induce nuclear localization of nuclear factor-kappaB, cytokine production, and cell proliferation, as well as enhance the potency of dendritic cell-based tumor vaccines when systemically delivered to mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.